Eli Lilly faces patent challenge from a long-ago collaboration

Article Abstract:

Eli Lilly and Co. of the United States is embroiled in a patent infringement case with a Stanford medical researcher, Gerald Crabtree over the licensing of the Xigris drug. Mr. Crabree researched gene Protein C, the ground work for the development of Xigris, for six years in the 1980's and was not credited as a co-discoverer so he did not receive royalties. Pharmaceutical companies often use overlapping research when developing a drug which may lead to muddy waters for patent licensing.

Patent infringement

---

Eli Lilly settles Alaska's Zyprexa suit for $15 million

Article Abstract:

To avoid a state class action, pharmaceutical company Eli Lilly & Co. will settle a suit with the government of Alaska for $15 million over the company's alleged failure to properly notify consumers about drug Zyprexa's side effects. Article discusses the suit's legal and financial implications for the company at the national level.

Alaska, Drugs, Adverse drug reactions, Governmental investigations, Government investigations

---

Lilly settles 18,000 Zyprexa claims, but more loom

Article Abstract:

Eli Lilly and Co. has settled 18,000 product liability claims, but faces many more. The company allegedly failed to adequately warn consumers that its antipsychotic drug Zyprexa can cause diabetes.

Similar abstracts:

• Abstracts: Licenses are the biggest hurdle to a deal for Harrah's. Starwood's Secret
• Abstracts: UBS role in Dubai-Almatis deal is big vote for leveraged finance. Ashley launches effort to acquire Newcastle United
• Abstracts: 60-knot boat chases abalone poachers. Furuno launches new radar. Cat develops higher ratings for marine engine family
• Abstracts: Steel offer in China tests players' resolve: takeover bid shows scramble in sector; doubts about move. Subprime-lending worries hit overseas markets: investors fear damage to huge U.S. economy will hurt Europe, Asia
• Abstracts: ECB tops off a day of rate increases. European policy makers hint at interest-rate rise

This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.